Eli Lilly is buying another European cancer firm Mablink Bioscience

October 18, 2023 07:01 AM PDT | By Invezz

Eli Lilly is buying another European cancer firm Mablink Bioscience — Image source: Invezz

It’s the 2^nd cancer company Lilly bought this month

Clearly, the pharmaceutical behemoth is committed to expanding its footprint in oncology.

Earlier this month, Lilly was reported willing to spend $1.4 billion to take over Point Biopharma Global Inc – a Pittsburgh-headquartered company that is also committed to cancer treatment.

All in all, the New York listed firm has now made at least six acquisitions this year, including Emergence Therapeutics that Mablink Bioscience had partnered with in 2021.

Focus on obesity drugs in recent months has pushed the market cap of Eli Lilly & Co to near $600 billion which makes it the most valuable pharmaceutical company in the United States.

Watch here: https://www.youtube.com/embed/WtMk1hBD43g?feature=oembed

Eli Lilly to report its Q3 earnings in early November

The Mablink acquisition was first reported last night by Endpoints News that cited Dan Skovronsky – the Chief Scientific Officer of Eli Lilly & Co.

What the Indiana-based giant is paying to buy Mablink Bioscience that reported pre-clinical data for MBK-103 in April, remains unknown, though. The French company plans on pushing its lead ADC candidate into the first-in-human trial in 2024.

Eli #Lilly initially partnered with #ImmunoGen in 2011 to delve into ADCs, but their sole candidate, #LY3076226 (FGFR3), was halted during phase 1 trials.

In 2019, the ADC market was revitalized by the introduction of #TDxd. Recognizing this shift, Lilly renewed its partnership… https://t.co/r1U311NWRl

— Byung-June Park (@onco_park) October 18, 2023

The stock market news arrives only a couple weeks before Lilly is expected to report its Q3 results. Consensus is for it to earn 70 cents a share this quarter versus $1.98 per share a year ago.

Wall Street currently has a consensus “overweight” rating on this big pharma stock that has already nearly doubled over the past eight months.

The post Eli Lilly is buying another European cancer firm Mablink Bioscience appeared first on Invezz

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.